Som Innovation Biotech, S.l.

Digna Biotech, S.l.

Som Innovation Biotech, S.a.

University of Minnesota

Raúl Insa Boronat

Marc Centellas Casado

Nuria Reig Bolaño

Núria Gavaldà Batalla

Santiago Esteva Gras

Núria Reig Bolaño

Núria Reig Bolano

Nuria Gavaldà Batalla

Anna Nardi Ricart

Oscar Huertas Gambín

Josep Maria Suñé Negre

Josep María Suñé Negre

Aileen Ferré Ferré

Óscar Huertas Gambin

Gal-la Pericot Mohr

Gal⋅Ia Pericot Mohr

Galla Pericot Mohr

Luca Signorile

Javier Dotor De Las Herrerías

Miguel Quintanilla Avila

Óscar Huertas Gambín

Yoko Asakura

Atsushi Asakura

Josep María SuÑÉ Negre

The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of phenylketonuria, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.

Triamterene or nolatrexed for use in the treatment of phenylketonuria

The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.

Sustained release compositions comprising micronized tolcapone

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

Therapy for transthyretin-associated amyloidosis

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

(RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders

A method to inhibit the formation of skin tumors at early stages and their subsequent progression to carcinoma in a mammal is described, the method including the topical application to the mammal's skin of a composition that includes a therapeutically effective amount of disitertide, together with pharmaceutically acceptable carriers or diluents.

Peptide for the prophylactic or therapeutic treatment of skin tumors in initial stages

Growing community of inventors

Barcelona, Spain

Raúl Insa Boronat